Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



April 2012, Volume 42 Number 4 , p 9 - 9



The FDA recently approved axitinib to treat patients with advanced renal cell carcinoma who've not responded to any other drug treatment. Axitinib is a kinase inhibitor that blocks tumor growth, angiogenesis, and cancer progression. Common adverse reactions include diarrhea, hypertension, fatigue, anorexia, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot syndrome), weight loss, vomiting, asthenia, and constipation.Hypertension should be well controlled before initiating axitinib because of the risk of hypertensive crisis. The drug hasn't been studied in patients with evidence of untreated brain metastasis or recent active gastrointestinal bleeding and shouldn't be used in these patients.Source: FDA approves Inlyta to treat patients with a type of advanced kidney cancer. . Prescribing information: .A new study has revealed that statin therapy improves

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: